Osimertinib Plus Chemotherapy Improves PFS in EGFR+ Advanced NSCLC
The combination of osimertinib and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.
Source: onclive.com